- email:registrations@informa-ls.com
- phone:+44(0)20 7017 7481
 |
Vaccines Europe 2011
30 November - 1 December 2011
|
Vaccines Europe 2011- Europe's leading conference providing the latest technological advances in delivery platforms, vectors, adjuvants, production and stability strategies for the newest vaccine targets in the industry including DNA vaccines and cancer vaccines
Europe’s Premier Vaccines Forum - Interact with the leading experts in the vaccine field and hear the latest vaccine research, improved production methods, analytical advances and regualtory updates
Vaccines Europe is a hugely successful event attracting some of the leading international experts, academics and service providers in the industry. The conference is focused on vital topics including the development of both prophylactic and therapeutic vaccines, emerging vaccine markets, vaccine characterisation, quality control, scale-up and manufacturing. This conference also provides talks on the latest cutting edge research and technologies in new vaccine targets.
Brand new for 2011: This event focuses on revealing cutting edge research and manufacturing strategies for the development of tropical disease vaccines, cancer vaccines and immunotherapy, as well as influenza vaccines, H5N1 vaccine and other vaccines in development. This event provides the latest academic and industry insight on novel vectors, adjuvants and delivery systems, as well as providing a great netwroking opportunity for all delegates.
This year Vaccines Europe will once again be a streamed event allowing delegates to interact between the different options. The event is also co-located with Cell Therapy Manufacturing and Vet Vaccines
Keep updated via our website to ensure you are well informed about new speakers and the topics that will be discussed at this event…..
PLENARY PRESENTATIONS
Informa Life Sciences prides itself on recruiting the leading experts in the field of vaccines. This year, we have the following industry speakers who represent both new and well-established vaccine companies, and who will be giving their industry insights into the latest therapeutic vaccine focus and technological developments. The 2011 plenary session will be led by:
Dr Niranjan Y. Sardesai, Senior Vice President, Research & Development, Inovio, USA and Dr Laura Martin, Development Project Leader, Novartis Institute of Global Health, Italy
Hear presentations on the latest applications of DNA vaccines and
DO NOT MISS OUR 2011 KEYNOTE PRESENTATIONS
- Dr Jeff Maisonneuve, Scientific Director, Pneumococcal Vaccine Project, Vaccine Development Global Program, PATH, USA, updates you on PATH's latest developments in their pneumococcal vaccine
- Dr Cécile Ponsar, Director, Product & Process Technical Support, GSK Biologicals, Belgium and Dr Nancy Cauwenberghs, Director, Technical Regulatory Affairs, GSK Biologicals, Belgium, present on GSK's latest pilot study of Quality by Design for vaccine development
45 industry and regulatory representatives including the EU commission, WHO, FDA, RIVM and many more....
DO NOT MISS: +30 industry representatives, including GSK Biologicals, MedImmune, Novartis, Pfizer, Sanofi Pasteur and 10 SME presentations
45 industry and regulatory representatives including the EU commission, WHO, FDA, RIVM and many more....
Dr John Siu Lun Tam
Technical Officer, Initiative for Vaccine Research
WHO
|
Dr Jeffrey Ulmer
Global Head, External Research
Novartis Vaccines & Diagnostics
|
Dr Andreas Holtel
Scientific Officer
European Commission
|
Dr Theone Kon
Senior Scientist, Down Stream Processing
RIVM
|
Dr Cara Fiore
Regulatory Scientist
FDA, CBER
|
Dr Niranjan Y. Sardesai
Senior Vice President R&D
Inovio
|
Dates and Venues
30 Nov 2011 - 01 Dec 2011
Sheraton Brussels Hotel, Belgium
Testimonials
"Very informative, very useful learning"
"A useful introduction to the process challenges facing the vaccine industry"
"Very good opportunity for networking and for scientific interactions between manufacturing, QC, QA and CMOs"
Conference Sponsors
Spotlight Presentation Sponsors
Promotional Participant
Exhibitors
Benchmark your Vaccine Programmes Against 30+ Leading Companies
In partnership with
NEW EVENT SPONSOR
We are happy to welcome Cobra Biologics Ltd. to our Vaccines Europe event. Dr Rocky Cranenburgh will be presenting:
Eliminating Antibiotic Resistance Genes for Vaccine Production and Delivery
Do not miss this presentation on Day 2, Stream B
Europe’s Premier Vaccines Forum - Presenting the latest research and development updates from the leading biopharm and regulatory experts in the field
Gain insight on the following topics:
- FDA, EU Commision and the WHO insight into authority requirements for vaccine projects
- Latest industry experience developing cancer vaccines and immunotherapy
- Development and charactersation of vaccine adjuvants
- Novel vaccine delivery systems: DNA vaccines
- Development and manufacturing strategies: Quality by Design
- Stability and delivery of vaccines
- Vaccines for tropical diseases: Including Malaria, TB, Influnza and more
- Viral safety
and much more..................
Other Events That Will Interest You
NEW SPEAKER ANNOUNCEMENT: Representative from the WHO discussing pandemic influenza vaccines
The only European conference where the World Health Organisation present first hand on the importance of improving existing and future supply and demand: seasonal and pandemic influenza vaccines. DO NOT MISS this one off opportunity to hear Dr. John Siu Lun Tam, Technical Officer, Initiative for Vaccine Research, Immunisation, Vaccines and Biologicals, WHO discuss how this constant concern is being addressed by the health authorities and applied in industry.
PROGRAMME CORRECTION
Informa Life Sciences would like to rectify the information erroneously advertised and published on page one of the Vaccines Europe 2011 programme. All presentations at this event on behalf of GlaxoSmithKline will not be based upon 'GSK unpublished data'
ATMI PRESENTATION ANNOUNCEMENT
Do not miss ATMI presenting at our Vaccines Europe 2011 conference on:
Renew manufacturing processes of “old” vaccines – ATMI approach to design of single-use bioreactors
With the rise of ever increasingly more complex vaccines, ATMI can help you discover how to overcome some of the common manufacturing pitfalls that are often encountered
Alternate Language Options:
FOR THE FIRST TIME EVER- EU COMMISSION PRESENTS........
Do not miss hearing Dr Andreas Holtel from the European Commission discussing:
BRAND NEW CRUCELL & PATH PRESENTER
Vaccines Europe 2011 would like to announce Dr Macaya Douoguih, Director, Clinical Development, Crucell who will be representing Crucell at this conference. In addition, Dr Jeff Maisonneuve Senior Director of the Pneumococcal Vacine Project at PATH will be discussing the pneumococcal vaccines of the future.
DO NOT MISS our 2 interactive workshops and informative evening seminar
x2 BRAND NEW WORKSHOPS:
OPTION 1) State of the art cancer vaccines and immunotherapy
OPTION 2) Quality by Design in vaccine development and manufacturing
x1 EVENING SEMINAR:
FDA and RIVM representatives discuss the EU and US Regulations for Comparability Studies
Co-located with Informa's Cell Therapy Manufacturing and Veterinary Vaccines Congress
Spotlight Presentation Sponsors
Exhibitors
